Table 2.

Immunological parameters of the patients with mutations in ARPC1B at the first evaluation.

Patient	IgE	IgG	IgA	IgM	CD3	CD19	CD4	CD8	NK	T cell prolif. (PHA)	T cell prolif. (CD3+CD28)
	IE/L	g/L			109 cells/L					%	%
NV1	0–100	7.0–16.0	0.7–5.0	0.4–2.8	0.7–1.9	0.1–0.4	0.4–1.3	0.2–0.7	0.04–0.2	29–57	50–85
P1	1746↑	13.4	0.98	2.52	0.626↓	0.562↑	0.305↓	0.498	0.369	15↓	52
P2	932↑	11.3	4.7	0.85	0.967	0.521↑	0.459	0.546	0.468	22↓	70
P3	716↑	13.6	6.3↑	0.6	1.006	0.542↑	0.730	0.126↓	0.066↓	33	66
NV2	0-60	4.7-12.0	0.14-0.91	0.4-1.5	2.2-5.5	0.9-2.5	1.1-3.6	0.5-1.8	0.1-1.1	29-57	50-85
P4	<19	12.4↑	2.21↑	1.33	1.551↓	2.066	1.024↓	0.408↓	0.777	38	77

Immunoglobulin classes were measured in serum. The concentration of IgE is in IE/L, and IgG, IgA, IgM in g/L. The concentration of lymphocytes subpopulations are presented as ×10⁹ cells/L, the proliferation of T lymphocytes after stimulation with PHA or CD3 and CD28 in percentage of proliferating cells. CD3, T lymphocytes; CD19, B lymphocytes; CD4, helper T cells; CD8, cytotoxic T cells; NK, Natural killer cells; PHA, phytohaemagglutinin; anti-CD3, anti-CD28 – monoclonal antibodies, P, patients, NV1, normal values for adults, NV2, normal values for 16 month. An arrow indicates deviation from normal values (15, 16).